Last updated: August 25, 2026
Claritin-D is a mature U.S. over-the-counter allergy and nasal-congestion product combining loratadine with pseudoephedrine. Its commercial position is supported by strong brand recognition, seasonal demand, and a differentiated decongestant ingredient. Its growth is constrained by generic substitution, pseudoephedrine purchasing restrictions, retailer controls, and the lack of publicly reported product-level revenue.
The product’s financial trajectory is best characterized as stable-to-declining in branded sales, with value retained through the wider Claritin franchise and the enduring consumer demand for oral antihistamine-decongestants. Bayer, the current Claritin brand owner, does not disclose Claritin-D revenue separately. Public financial data support an assessment of category and portfolio performance rather than a precise product sales estimate.
What is Claritin-D and how does it make money?
Claritin-D contains two active ingredients:
| Product |
Loratadine |
Pseudoephedrine sulfate |
Dosing |
| Claritin-D 12 Hour |
5 mg |
120 mg |
One tablet every 12 hours |
| Claritin-D 24 Hour |
10 mg |
240 mg |
One tablet every 24 hours |
Loratadine is a second-generation antihistamine used for allergy symptoms. Pseudoephedrine is an oral nasal decongestant. The combination addresses both allergic symptoms and congestion, allowing Claritin-D to command a premium over plain loratadine products.
Claritin-D is sold primarily through:
- Pharmacies and drugstores
- Mass retailers
- Grocery stores
- Warehouse clubs
- E-commerce channels
- Seasonal allergy merchandising programs
The commercial model is primarily consumer packaged goods rather than prescription pharmaceutical sales. Revenue depends on retail sell-through, wholesale distribution, brand pricing, promotional activity, product availability, and seasonal inventory.
What is the FDA regulatory status of Claritin-D?
Claritin-D is an FDA-approved nonprescription drug product. Its labeling identifies loratadine and pseudoephedrine as active ingredients and carries the standard warnings associated with antihistamines and oral decongestants.
Pseudoephedrine creates a regulatory distinction from ordinary over-the-counter allergy products. Under the Combat Methamphetamine Epidemic Act of 2005, pseudoephedrine products must be sold from behind the pharmacy counter or in a restricted-access area. Retailers must verify purchaser identity, maintain transaction records, and enforce federal purchase limits. State requirements can be stricter.[1]
The restrictions affect Claritin-D in four ways:
- Consumers cannot obtain the product from conventional open-shelf allergy aisles in most U.S. stores.
- Retailers must manage inventory through pharmacy systems.
- Consumers face daily and monthly purchase limits.
- Out-of-stock events are more likely when retailer controls or allocation systems are restrictive.
Claritin-D is therefore regulated as an OTC product but purchased through a controlled retail channel.
What is the Orange Book status of Claritin-D?
Claritin-D does not have the same commercial exclusivity structure as a newly approved prescription drug. Its principal U.S. economic protections are brand equity, approved labeling, distribution, and consumer recognition rather than an active blocking patent estate.
FDA Orange Book treatment is less commercially important for Claritin-D than for prescription products because:
- The product is marketed without a prescription.
- Generic competitors can market loratadine-pseudoephedrine products under separate approvals or OTC pathways.
- The key active ingredients are long established.
- The historical composition and formulation patents associated with loratadine have expired.
The Orange Book should not be treated as a reliable measure of Claritin-D’s current competitive protection. Product-specific FDA approval records and current labeling are more relevant for regulatory status, while retail scanner data are more relevant for market share.
What patents protect Claritin-D?
Claritin-D has limited current patent protection. The historic patent estate around loratadine and the Claritin brand was developed by Schering-Plough and related entities, but the principal pharmaceutical patents covering loratadine expired years ago.
The relevant protection categories were:
| Protection category |
Historical role |
Current commercial effect |
| Loratadine compound patents |
Protected the active antihistamine |
Expired |
| Loratadine formulations |
Covered dosage forms and delivery characteristics |
Broadly expired or vulnerable to design-around |
| Combination product claims |
Covered loratadine with pseudoephedrine in particular formulations |
Limited current blocking value |
| Manufacturing processes |
Covered specific production methods |
Potentially relevant only for narrow processes |
| Claritin trademarks |
Protected brand identity |
Continues while maintained and used |
| Product labeling |
Defines approved indications and warnings |
Regulatory protection, not market exclusivity |
Claritin-D’s current moat is therefore commercial rather than patent-based. The brand name, retailer relationships, consumer familiarity, and perceived reliability are more important than exclusivity rights.
How strong is the Claritin-D patent estate?
The patent estate is weak as a barrier to generic entry. A competitor can generally rely on established active ingredients and develop a bioequivalent or therapeutically equivalent product without needing a license from Bayer for the Claritin brand.
The remaining legal protections are more likely to involve:
- Trademark infringement
- False or misleading advertising
- Trade dress
- Labeling compliance
- Narrow manufacturing claims
- Retail or distribution agreements
These rights can support litigation against imitation branding or deceptive marketing, but they do not prevent broad generic competition.
When does Claritin-D lose exclusivity?
Claritin-D effectively lost meaningful pharmaceutical exclusivity years ago. Generic loratadine and pseudoephedrine products have been available for many years, and the product’s active ingredients are no longer protected by a current foundational patent barrier.
The relevant commercial timeline is:
| Period |
Event |
Market effect |
| 1980s-1990s |
Loratadine developed and commercialized |
Creation of the Claritin franchise |
| 1990s |
Claritin becomes a major prescription allergy brand |
High branded pricing and physician-driven demand |
| 2002 |
Claritin transitioned to OTC status in the U.S. |
Expanded consumer access and changed pricing economics |
| 2000s |
Generic loratadine and loratadine-pseudoephedrine products expand |
Increased price competition |
| 2005 onward |
Federal pseudoephedrine controls take effect |
Greater retail friction for Claritin-D |
| 2010s |
Brand ownership moves to Bayer after its acquisition of Merck’s consumer-care business |
Integration into Bayer Consumer Health |
| 2020s |
Mature OTC category with generic and private-label competition |
Brand premium depends on marketing and availability |
The 2002 OTC switch was commercially significant. It increased household access to Claritin and removed prescription reimbursement as the primary purchasing mechanism. The change also placed the brand into direct competition with store brands and private-label products.
Which companies challenge Claritin-D?
Claritin-D faces competition from branded, generic, and alternative-product manufacturers. Major competitive groups include:
- Perrigo
- Kenvue, through the broader allergy and cold-care portfolio
- Haleon
- CVS Health and other retailer private-label businesses
- Walgreens Boots Alliance private-label suppliers
- Walmart and warehouse-club private-label suppliers
- Generic manufacturers and contract manufacturers supplying pharmacy channels
The closest substitutes are loratadine-pseudoephedrine products sold under generic or store-brand labels. Broader substitutes include:
- Plain loratadine
- Cetirizine-pseudoephedrine combinations
- Fexofenadine-pseudoephedrine products
- Intranasal corticosteroids
- Topical nasal decongestants
- Prescription nasal sprays
Claritin-D’s competitive advantage is strongest when consumers want a single oral product that combines non-sedating allergy relief with systemic congestion relief.
How does Claritin-D compare with competing allergy drugs?
| Product category |
Main benefit |
Principal limitation |
Competitive relationship |
| Claritin-D |
Allergy relief plus congestion relief |
Pseudoephedrine restrictions and stimulant-related warnings |
Direct branded and generic competition |
| Plain Claritin |
Allergy relief |
Does not directly address nasal congestion as strongly |
Cannibalizes Claritin-D when congestion is limited |
| Zyrtec-D |
Cetirizine plus pseudoephedrine |
More potential sedation for some users |
Direct combination-product competitor |
| Allegra-D |
Fexofenadine plus pseudoephedrine |
Higher price and limited availability in some stores |
Direct combination-product competitor |
| Flonase and other nasal steroids |
Strong nasal symptom control |
Requires regular use and different administration behavior |
Substitution for congestion and allergic rhinitis |
| Sudafed products |
Decongestant relief |
Does not treat the underlying allergic response |
Complementary or partial substitute |
Claritin-D benefits from the Claritin name but can lose consumers to products with stronger perceived congestion relief, lower prices, or better availability behind the pharmacy counter.
What are the main market dynamics affecting Claritin-D?
Seasonal demand
Claritin-D sales are concentrated around spring and fall allergy seasons, although indoor allergens and year-round congestion provide a baseline. Weather, pollen intensity, regional allergy conditions, respiratory illness trends, and retailer promotional calendars influence demand.
Seasonality creates working-capital and inventory risks. Manufacturers and retailers must build inventory ahead of peak pollen periods. A weak season can leave excess inventory, while a severe season can produce stockouts.
Generic substitution
Generic and private-label competition limits Claritin-D’s pricing power. Consumers who recognize the active ingredients can switch to lower-priced alternatives, particularly in pharmacy and mass-retail channels.
The brand retains pricing power among consumers who value:
- Familiarity with Claritin
- Perceived quality consistency
- Convenience
- Packaging recognition
- Prior treatment experience
The premium is narrower than it was during the prescription and early OTC periods.
Pseudoephedrine access
Pseudoephedrine rules are the most distinctive structural constraint. Consumers must interact with pharmacy staff, comply with purchase limits, and sometimes provide identification. These steps increase friction relative to open-shelf allergy products.
The same restriction also limits certain competitive threats. Products containing pseudoephedrine cannot be freely distributed through ordinary retail shelves, creating a more controlled competitive environment than for plain loratadine.
Retail execution
Availability is critical. A consumer seeking Claritin-D may choose another product if the pharmacy counter is closed, the SKU is out of stock, or the purchase process is inconvenient. This makes retailer coverage and inventory management unusually important for an OTC medicine.
What is the financial trajectory of Claritin-D?
Bayer does not report Claritin-D revenue, gross margin, market share, or operating profit as separate line items. The product is included within Bayer Consumer Health, which reports at a broader category and regional level.[2]
The product-level trajectory can therefore be assessed through commercial structure:
| Driver |
Directional effect on Claritin-D |
| Brand recognition |
Positive |
| Mature allergy category |
Neutral to negative for unit growth |
| Generic competition |
Negative for price and share |
| Pseudoephedrine differentiation |
Positive for congestion-focused demand |
| Pharmacy-counter restrictions |
Negative for convenience and conversion |
| OTC consumer access |
Positive for broad reach |
| Seasonal allergy intensity |
Variable, potentially positive |
| Retailer private labels |
Negative |
| Inflation and price increases |
Positive for reported sales, negative for volume |
| E-commerce |
Mixed because pseudoephedrine fulfillment remains controlled |
Claritin-D likely generates a smaller and more mature revenue stream than the broader Claritin franchise, which includes plain Claritin products and multiple dosage forms. Its financial contribution is strategically useful but unlikely to be material to Bayer’s consolidated results on a standalone basis.
For Bayer, the product’s value is likely measured through:
- Portfolio breadth
- Retailer shelf and pharmacy-counter presence
- Consumer retention
- Cross-selling across allergy products
- Contribution to seasonal category performance
- Brand support for the broader Claritin franchise
What generic launch risks exist for Claritin-D?
Generic launch risk is already realized rather than prospective. The major economic issue is continued share migration and price compression, not a future patent cliff.
Potential generic scenarios include:
| Scenario |
Likely outcome |
| Generic price competition intensifies |
Branded unit share declines and promotional spending rises |
| Retailers expand private-label distribution |
Bayer loses high-volume value-oriented consumers |
| Consumers prioritize congestion relief |
Combination products retain demand |
| Consumers shift to nasal steroids |
Claritin-D category volume declines |
| Pharmacy access becomes more restrictive |
Conversion and repeat purchase rates weaken |
| Brand advertising increases |
Bayer protects premium but margins may compress |
A successful generic competitor does not need to defeat a current Claritin-D patent. It needs regulatory authorization, compliant labeling, manufacturing capacity, retailer access, and competitive pricing.
What patent litigation affects Claritin-D?
No major current U.S. patent litigation is central to Claritin-D’s commercial outlook based on the public record commonly used for drug patent analysis. The historical litigation and exclusivity issues surrounding loratadine are no longer the primary market variable.
Current legal exposure is more likely to arise from:
- Trademark enforcement involving “Claritin”
- Counterfeit products
- Misleading comparative advertising
- FDA labeling violations
- Retail distribution disputes
- Product liability claims
- Manufacturing or quality-control issues
Are there Paragraph IV challenges to Claritin-D?
Paragraph IV litigation is not a meaningful current risk driver for Claritin-D. Paragraph IV challenges are most relevant when an applicant seeks approval for a generic drug while asserting that listed patents are invalid, unenforceable, or not infringed. Claritin-D’s key active-ingredient patents are historic, and the product competes in a mature OTC environment.
The absence of a current Paragraph IV event does not protect the brand. It reflects the age and competitive status of the product.
Does Claritin-D face biosimilar risk?
Claritin-D has no biosimilar risk. It is a small-molecule combination drug, not a biologic. Its competitors are generic, private-label, and therapeutic substitutes rather than biosimilars.
The relevant regulatory pathways are abbreviated or OTC drug pathways, depending on the product and approval structure. Biosimilar approval under the Public Health Service Act does not apply.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are moderate but manageable. A competitor must produce two active ingredients in a compliant fixed-dose product and meet requirements for:
- Content uniformity
- Dissolution
- Stability
- Tablet compression
- Packaging
- Tamper resistance
- Labeling
- Good manufacturing practice
- Controlled pseudoephedrine distribution
Pseudoephedrine procurement and retail controls create more operational complexity than plain loratadine. However, these requirements do not create a durable proprietary barrier for large generic manufacturers.
Geographic protection is also limited. Claritin-D’s strongest commercial relevance is in the United States, where pseudoephedrine restrictions shape distribution. Other countries regulate loratadine-pseudoephedrine combinations differently, and the Claritin brand may have different owners, formulations, or market positions across jurisdictions.
What licensing deals affect Claritin-D?
The important transaction affecting Claritin is Bayer’s acquisition of Merck’s consumer-care business in 2014. The transaction transferred the U.S. Claritin franchise to Bayer Consumer Health, along with other established consumer-health brands.[3]
No major publicly disclosed licensing arrangement appears to define Claritin-D’s current commercial economics. The brand is primarily managed within Bayer’s consumer-health portfolio rather than through a publicly reported third-party royalty structure.
What is the commercial outlook for Claritin-D?
Claritin-D remains commercially viable because it combines a recognized allergy brand with a clinically familiar decongestant. Its outlook is stable but mature.
The strongest positive factors are:
- Persistent allergic-rhinitis prevalence
- Consumer demand for combination symptom relief
- High Claritin brand awareness
- Seasonal category relevance
- Continued pharmacy distribution
The main negative factors are:
- Low current patent protection
- Generic and private-label substitution
- Pseudoephedrine purchasing friction
- Competition from nasal steroids
- Limited product-level growth opportunities
- Lack of meaningful prescription-channel exclusivity
The likely financial pattern is modest nominal growth during periods of price inflation, offset by flat or declining unit volumes. Bayer can protect revenue through brand investment, pricing, packaging, retailer execution, and portfolio management, but the product is unlikely to return to the growth rates associated with its prescription launch or initial OTC transition.
Key Takeaways
- Claritin-D is an OTC loratadine-pseudoephedrine combination marketed by Bayer.
- The principal U.S. products are Claritin-D 12 Hour and Claritin-D 24 Hour.
- Pseudoephedrine access rules are the product’s most important regulatory and commercial constraint.
- The core loratadine patent estate is expired, leaving limited current patent-based exclusivity.
- Generic and private-label competition is established and will continue to pressure price and share.
- Claritin-D has no biosimilar risk because it is a small-molecule combination drug.
- Bayer does not disclose Claritin-D revenue separately, preventing a precise product-level financial forecast.
- The product’s value lies in brand recognition, seasonal demand, and combination relief rather than patent protection.
- The commercial outlook is mature and defensive, with nominal revenue supported by pricing and brand retention rather than strong unit growth.
FAQs About Claritin-D Market and Exclusivity
Is Claritin-D still under patent protection?
No material foundational patent protection appears to remain for the active ingredients or the core combination. Current competitive protection comes mainly from the Claritin trademark, branding, distribution, and regulatory compliance.
Why is Claritin-D kept behind the pharmacy counter?
Claritin-D contains pseudoephedrine, which is subject to federal sales controls because pseudoephedrine can be diverted for illicit methamphetamine production.
Can generic companies sell loratadine-pseudoephedrine products?
Yes. Generic and store-brand loratadine-pseudoephedrine products compete with Claritin-D, subject to FDA authorization, labeling requirements, and pseudoephedrine sales controls.
Is Claritin-D more profitable than plain Claritin?
Public filings do not provide product-level margins. Claritin-D can command a combination-product premium, but its profitability is reduced by controlled distribution, generic competition, and higher retail execution requirements.
Who owns the Claritin-D brand?
Bayer owns and markets the Claritin brand in the United States through its Consumer Health business following Bayer’s acquisition of Merck’s consumer-care operations.
References
- U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005, Pub. L. No. 109-177, Title VII.
- Bayer AG. (2024). Annual report 2023. Bayer AG.
- Bayer AG. (2014). Bayer completes acquisition of consumer care business from Merck & Co., Inc. Bayer AG.
- U.S. Food and Drug Administration. (n.d.). Claritin-D drug labeling and approval information. Drugs@FDA.
- U.S. Food and Drug Administration. (n.d.). FDA Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
